1. Home
  2. DFLI vs LITS Comparison

DFLI vs LITS Comparison

Compare DFLI & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dragonfly Energy Holdings Corp. (NV)

DFLI

Dragonfly Energy Holdings Corp. (NV)

HOLD

Current Price

$2.05

Market Cap

49.0M

Sector

Technology

ML Signal

HOLD

LITS

Lite Strategy Inc.

N/A

Current Price

$1.15

Market Cap

41.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DFLI
LITS
Founded
2020
2000
Country
United States
United States
Employees
N/A
4
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
41.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DFLI
LITS
Price
$2.05
$1.15
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.25
N/A
AVG Volume (30 Days)
378.4K
236.0K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$51.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$0.95
52 Week High
$5.15
$3.03

Technical Indicators

Market Signals
Indicator
DFLI
LITS
Relative Strength Index (RSI) 48.28 50.84
Support Level $1.56 $1.17
Resistance Level $2.24 $1.26
Average True Range (ATR) 0.16 0.05
MACD 0.04 0.00
Stochastic Oscillator 49.98 54.05

Price Performance

Historical Comparison
DFLI
LITS

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: